All In Biotech

Drug Trial Radar · NCT04792489

DALY II USA/ MB-CART2019.1 for DLBCL

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

May 25, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Miltenyi Biomedicine GmbHIndustry
Sponsor type
Industry
First posted
Mar 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.

Conditions

  • Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapsed Diffuse Large B Cell Lymphoma
  • High Grade B-cell Lymphoma (HGBCL)
  • Primary Mediastinal B-cell Lymphoma (PMBCL)
  • Transformed Lymphoma
  • Central Nervous System Lymphoma
  • Mantle Cell Lymphoma (MCL)
  • Richter Transformation
  • Transplant-ineligible 2nd Line DLBCL

Interventions

  • zamtocabtagene autoleucel (MB-CART2019.1)Biological

    Chimeric antigen receptor (CAR) T cell therapy

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • BendamustineDrug

    Lymphodepleting chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: through study completion, up to 2 years

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • UC San Diego Health

    La Jolla, California · Recruiting

  • Stanford University

    Stanford, California · Recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Baptist Health Miami Cancer Institute

    Miami, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Robert H Lurie Cancer Center

    Chicago, Illinois · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University, St. Louis

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Terminated

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center - Division of Hematologic Malignancies

    Durham, North Carolina · Recruiting

  • The Ohio State University Wexner Medical Center James Cancer

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University Knight Cancer Institute

    Portland, Oregon · Recruiting

  • Allegheny Health Network Cancer Institute

    Pittsburgh, Pennsylvania · Recruiting

  • University of Pittsburgh - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Withdrawn

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Transplant Institute

    San Antonio, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • University of Alberta Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.